1. Home
  2. CPRX

as 08-29-2025 2:31pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).

Founded: 2002 Country:
United States
United States
Employees: N/A City: CORAL GABLES
Market Cap: 2.6B IPO Year: 2006
Target Price: $33.20 AVG Volume (30 days): 1.5M
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 1.65 EPS Growth: 183.96
52 Week Low/High: $19.00 - $26.58 Next Earning Date: 08-06-2025
Revenue: $558,499,000 Revenue Growth: 28.55%
Revenue Growth (this year): 16.51% Revenue Growth (next year): 9.58%

CPRX Daily Stock ML Predictions

Stock Insider Trading Activity of Catalyst Pharmaceuticals Inc. (CPRX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Tierney David S CPRX Director Aug 27 '25 Sell $20.20 26,000 $525,200.00 379,620
Daly Richard J CPRX President and CEO Aug 26 '25 Sell $20.62 22,970 $473,641.40 226,794
Miller Steve CPRX Chief Op. & Scientific Officer Aug 26 '25 Sell $20.28 115,000 $2,332,200.00 949,663
Sundaram Preethi CPRX Chief Strategy Officer Jun 10 '25 Sell $26.42 3,924 $103,648.84 41,081
MCENANY PATRICK J CPRX Director Jun 6 '25 Sell $26.03 200,000 $5,217,338.42 4,281,702

Share on Social Networks: